Development and evaluation of PIK75 nanosuspension, a phosphatidylinositol- 3-kinase inhibitor

European Journal of Pharmaceutical Sciences

Volumn 47, Issue 5, 2012, Pages 824-833

  Talekar, Meghna ^a   Kendall, Jackie ^b   Denny, William ^b   Jamieson, Stephen ^b   Garg, Sanjay ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Nanosuspension; Phosphatidylinositol 3 kinase inhibitor; PIK75; Solubility; Stability; Wet milling

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIK75 NANOSUSPENSION; UNCLASSIFIED DRUG;

ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; PARTICLE SIZE; PRIORITY JOURNAL; SURFACE PROPERTY; SUSPENSION; TISSUE DISTRIBUTION;

ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; HYDRAZONES; MALE; MICE; NANOSTRUCTURES; PARTICLE SIZE; PHOSPHATIDYLINOSITOL 3-KINASES; POWDER DIFFRACTION; SULFONAMIDES; SUSPENSIONS; TISSUE DISTRIBUTION; X-RAY DIFFRACTION;

EID: 84868680720     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.09.015     Document Type: Article

References (49)

1. A.G. Bader, S. Kang, and P.K. Vogt Cancer-specific mutations in PIK3CA are oncogenic in vivo Proc. Nat. Acad. Sci. USA 103 2006 1475 1479 (Pubitemid 43191190)
2. H.G. Brittain Physical Characterization of Pharmaceutical Solids. Drugs and Pharmaceutical Sciences 1995 Marcel Dekkar New York
3. L.C. Cantley The phosphoinositide 3-kinase pathway Science 296 2002 1655
4. A.M. Cerdeira, M. Mazzotti, and B. Gander Miconazole nanosuspensions: influence of formulation variables on particle size reduction and physical stability Int. J. Pharm. 396 2010 210 218
5. C. Chaussade, G.W. Rewcastle, J.D. Kendall, W.A. Denny, K. Cho, L.M. Gronning, M.L. Chong, S.H. Anagnostou, S.P. Jackson, N. Daniele, and P.R. Shepherd Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling Biochem. J. 404 2007 449 458 (Pubitemid 46953919)
6. P.P. Constantinides, M.V. Chaubal, and R. Shorr Advances in lipid nanodispersions for parenteral drug delivery and targeting Adv. Drug Deliv. Rev. 60 2008 757 767
7. R. Frédérick, C. Mawson, J.D. Kendall, C. Chaussade, G.W. Rewcastle, P.R. Shepherd, and W.A. Denny Phosphoinositide-3-kinase (PI3K) inhibitors: identification of new scaffolds using virtual screening Bioorg. Med. Chem. Lett. 19 2009 5842 5847
8. S. Ganta, J.W. Paxton, B.C. Baguley, and S. Garg Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery Int. J. Pharm. 367 2009 179 186
9. L. Gao, G. Liu, X. Wang, F. Liu, Y. Xu, and J. Ma Preparation of a chemically stable quercetin formulation using nanosuspension technology Int. J. Pharm. 404 2011 231 237
10. Y. Gao, Z. Li, M. Sun, C. Guo, A. Yu, Y. Xi, J. Cui, H. Lou, and G. Zhai Preparation and characterization of intravenously injectable curcumin nanosuspension Drug Deliv. 18 2011 131 142
11. Y. Gao, Z. Li, M. Sun, H. Li, C. Guo, J. Cui, A. Li, F. Cao, Y. Xi, H. Lou, and G. Zhai Preparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer Drug Dev. Ind. Pharm. 36 2010 1225 1234
12. M. Gymnopoulos, M.A. Elsliger, and P.K. Vogt Rare cancer-specific mutations in PIK3CA show gain of function Proc. Nat. Acad. Sci. USA 104 2007 5569 5574 (Pubitemid 47175721)
13. M. Hayakawa, K.I. Kawaguchi, H. Kaizawa, T. Koizumi, T. Ohishi, M. Yamano, M. Okada, M. Ohta, S.I. Tsukamoto, F.I. Raynaud, P. Parker, P. Workman, and M.D. Waterfield Synthesis and biological evaluation of sulfonylhydrazone- substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110α inhibitors Bioorg. Med. Chem. 15 2007 5837 5844 (Pubitemid 47043472)
14. J. Hecq, M. Deleers, D. Fanara, H. Vranckx, P. Boulanger, S. Le Lamer, and K. Amighi Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base Eur. J. Pharm. Biopharm. 64 2006 360 368 (Pubitemid 44585201)
15. K. Hirano, and C.A. Hunt Lymphatic transport of liposome-encapsulated agents: Effects of liposome size following intraperitoneal administration J. Pharm. Sci. 74 1985 915 921 (Pubitemid 15014130)
16. E. Hirsch, E. Ciraolo, A. Ghigo, and C. Costa Taming the PI3K team to hold inflammation and cancer at bay Pharmacol. Ther. 118 2008 192 205
17. ICH, 2012. Stability Testing of New Drug Substances and Products.
18. T.P. Johnston, and W.K. Palmer Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat Biochem. Pharmacol. 46 1993 1037 1042 (Pubitemid 23280545)
19. B. Karakas, K.E. Bachman, and B.H. Park Mutation of the PIK3CA oncogene in human cancers Br. J. Cancer 94 2006 455 459 (Pubitemid 43289745)
20. J.D. Kendall, G.W. Rewcastle, R. Frederick, C. Mawson, W.A. Denny, E.S. Marshall, B.C. Baguley, C. Chaussade, S.P. Jackson, and P.R. Shepherd Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110[alpha] inhibitors Bioorg. Med. Chem. 15 2007 7677 7687 (Pubitemid 47575920)
21. Z.A. Knight, B. Gonzalez, M.E. Feldman, E.R. Zunder, D.D. Goldenberg, O. Williams, R. Loewith, D. Stokoe, A. Balla, B. Toth, T. Balla, W.A. Weiss, R.L. Williams, and K.M. Shokat A Pharmacological map of the PI3-K family defines a role for p110α in insulin signaling Cell 125 2006 733 747
22. P. Kocbek, S. Baumgartner, and J. Kristl Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs Int. J. Pharm. 312 2006 179 186
23. S.J. Leevers, B. Vanhaesebroeck, and M.D. Waterfield Signalling through phosphoinositide 3-kinases: the lipids take centre stage Curr. Opin. Cell Biol. 11 1999 219 225 (Pubitemid 29164037)
24. P. Li, and L. Zhao Developing early formulations: practice and perspective Int. J. Pharm. 341 2007 1 19 (Pubitemid 47088122)
25. P. Liu, X. Rong, J. Laru, B. Van Veen, J. Kiesvaara, J. Hirvonen, T. Laaksonen, and L. Peltonen Nanosuspensions of poorly soluble drugs: preparation and development by wet milling Int. J. Pharm. 411 2011 215 222
26. S.M. Maira, C. Voliva, and C. Garcia-Echeverria Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery Expert Opin. Ther. Targets 12 2008 223 238 (Pubitemid 351284964)
27. Marone, R., Cmiljanovic, V., Giese, B., Wymann, M., 2008. Targeting phosphoinositide 3-kinase-Moving towards therapy. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1784, 159-185.
28. E. Merisko-Liversidge, P. Sarpotdar, J. Bruno, S. Hajj, L. Wei, N. Peltier, J. Rake, J.M. Shaw, S. Pugh, L. Polin, J. Jones, T. Corbett, E. Cooper, and G.G. Liversidge Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs Pharm. Res. 13 1996 272 278 (Pubitemid 26074194)
29. R.H. M′ller, S. Benita, and H.L. B′hm Emulsions and Nanosuspensions for the formulation of poorly soluble drugs 1998 MedPharm GmbH Scientific Publishers Germany pp. 54-102
30. R.H. M′ller, C. Jacobs, and O. Kayser Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future Adv. Drug Deliv. Rev. 47 2001 3 19 (Pubitemid 32209229)
31. M. Nakarani, P. Patel, J. Patel, R.S.R. Murthy, and S.S. Vaghani Cyclosporine a-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation Sci. Pharm. 78 2010 345 361
32. J. Pardeike, and R.H. Müller Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18 Int. J. Pharm. 391 2010 322 329
33. V.B. Patravale, A.A. Date, and R.M. Kulkarni Nanosuspensions: a promising drug delivery strategy J. Pharm. Pharmacol. 56 2004 827 840 (Pubitemid 38885975)
34. K. Peters, S. Leitzke, J.E. Diederichs, K. Borner, H. Hahn, R.H. Müller, and S. Ehlers Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine mycobacterium avium infection J. Antimicrob. Chemother. 45 2000 77 83 (Pubitemid 30060237)
35. X. Pu, J. Sun, M. Li, and Z. He Formulation of nanosuspensions as a new approach for the delivery of poorly soluble drugs Current Nanoscience 5 2009 417 427
36. K. Sigfridsson, S. Forssén, P. Holländer, U. Skantze, and J. de Verdier A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound Eur. J. Pharm. Biopharm. 67 2007 540 547 (Pubitemid 47225040)
37. H.A.C. Titulaer, W.M.C. Eling, D.J.A. Crommelin, P.A.M. Peeters, and J. Zuidema The parenteral controlled release of liposome encapsulated chloroquine in mice J. Pharm. Pharmacol. 42 1990 529 532 (Pubitemid 20343432)
38. M. Tsai, Z. Lu, J. Wang, T.K. Yeh, M.G. Wientjes, and J.L.S. Au Effects of carrier on disposition and antitumor activity of intraperitoneal paclitaxel Pharm. Res. 24 2007 1691 1701 (Pubitemid 47206619)
39. I.F. Uchegbu, J.A. Turton, J.A. Double, and A.T. Florence Drug distribution and a pulmonary adverse effect of intraperitoneally administered doxorubicin niosomes in the mouse Biopharm. Drug Dispos. 15 1994 691 707 (Pubitemid 24336800)
40. UKCR Cancer Worldwide - The Global Picture 2010 UK cancer research London
41. B. Van Eerdenbrugh, L. Froyen, J.A. Martens, N. Blaton, P. Augustijns, M. Brewster, and G. Van den Mooter Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling Int. J. Pharm. 338 2007 198 206 (Pubitemid 46779149)
42. B. Van Eerdenbrugh, J. Vermant, J.A. Martens, L. Froyen, J.V. Humbeeck, G. Van Den Mooter, and P. Augustijns Solubility increases associated with crystalline drug nanoparticles: methodologies and significance Mol. Pharm. 7 2010 1858 1870
43. I. Vivanco, and C. Sawyers The phosphatidylinositol 3-Kinase-AKT pathway in human cancer Nat Rev Cancer 2 2002 489 501 (Pubitemid 37328931)
44. K.S. Wagh, S.K. Patil, A.K. Akarte, and D.T. Baviskar Nanosuspension - a new approach of bioavailability enhancement Int. J. Pharm. Sci. Rev. Res. 8 2011 61 65
45. Y. Wang, Z. Liu, D. Zhang, X. Gao, X. Zhang, C. Duan, L. Jia, F. Feng, Y. Huang, Y. Shen, and Q. Zhang Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension Colloids Surf., B 83 2011 189 197
46. Z.G.M. Wout, E.A. Pec, J.A. Maggiore, R.H. Williams, P. Palicharla, and T.P. Johnston Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats J. Parenteral Sci. Technol. 46 1992 192 200 (Pubitemid 23052584)
47. X.G. Wu, M. Xin, L.N. Yang, and W.Y. Shi The biological characteristics and pharmacodynamics of a mycophenolate mofetil nanosuspension ophthalmic delivery system in rabbits J. Pharm. Sci. 100 2011 1350 1361
48. D. Xia, P. Quan, H. Piao, S. Sun, Y. Yin, and F. Cui Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability Eur. J. Pharm. Sci. 40 2010 325 334
49. S.H. Yalkowsky, J.F. Krzyzaniak, and G.H. Ward Formulation-related problems associated with intravenous drug delivery J. Pharm. Sci. 87 1998 787 796 (Pubitemid 28319406)